Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Talking it out: team approach may ease tough cancer decisions

NCT ID NCT07164365

Symptom relief Sponsor: Hospital Universitario San Ignacio Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tests whether an extra meeting with a team of doctors, a palliative care specialist, and a psychologist can help patients with advanced cancer feel less torn about their next treatment. 62 adults with metastatic lung, breast, colon, ovarian, or prostate cancer who need a third round of therapy will be randomly assigned to standard care or the extra team talk. The goal is to see if this shared decision-making approach reduces decisional conflict and improves satisfaction.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Interdisciplinary shared decision-making consultation (behavioral intervention)
What this could lead to
If successful, this approach could help patients with advanced cancer feel more confident and less conflicted about their treatment choices.
What could go wrong
This is a small, early-stage study with only 62 participants, so results may not apply broadly. The intervention is behavioral, not a drug, so it won't change the disease itself.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 62 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2025

Expected to finish

Apr 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥18 years * Diagnosed with metastatic lung, breast, colon, ovary, or prostate cancer * Have completed two prior lines of systemic therapy * Indication for third-line systemic therapy (chemotherapy, immunotherapy, or hormone therapy) * Under follow-up at Hospital San Ignacio * Capacity to provide informed consent * Exclusion Criteria:

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Decisional conflict, advanced/metastatic solid tumors, shared decision-making are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

breast carcinoma colorectal cancer lung cancer lung carcinoma metastatic prostate carcinoma neoplasm ovarian cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Decisional conflict, advanced/metastatic solid tumors, shared decision-making

Contacts and locations

Locations

  • Hospital Universitario San Ignacio

    Bogotá, Bogota D.C., 111111, Colombia

More trials for these conditions

Other studies related to the condition(s) this trial covers.